Self-Study 2025 Release II: Review of CNS Prophylaxis in Hematologic Malignancies
In some hematologic malignancies, such as Burkitt's lymphoma and acute lymphoblastic leukemia (ALL), central nervous system (CNS)-directed prophylaxis has significantly reduced CNS relapse and improved survival. However, its role in diffuse large B-cell lymphoma (DLBCL) and other hematologic malignancies is less clear, and practices vary wildly across institutions. Several challenges remain, including accurately stratifying patients at elevated risk of CNS relapse and developing effective therapies that can readily penetrate the blood-brain barrier while limiting toxicities. At the end of this self-study course, you will have the tools to administer preventative CNS-directed therapy that balances efficacy and toxicity with the patient's overall goals of care.
Review of CNS Prophylaxis in Adult Hematologic Malignancies
Author: Justine Preedit, PharmD, BCOP
Learning Objectives
- Differentiate various CNS prophylaxis methodologies for hematologic malignancies, focusing on the route, timing, dose, and frequency of pharmacologic therapies
- Recognize disease-specific risk factors that increase the likelihood of CNS relapse in hematologic malignancies
- Explain the challenges and future directions of novel therapies for preventing CNS disease in hematologic malignancies
- Evaluate the efficacy and appropriateness of CNS prophylaxis in acute leukemias and large B-cell lymphomas
Get it here
Knowledge Course for Pharmacists
Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post-Test with a 75% or higher.
All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.